软骨寡聚基质蛋白：慢性丙型肝炎肝纤维化的一个新的有前途的生物标志物。
Cartilage oligomeric matrix protein: a new promising biomarker of liver fibrosis in chronic hepatitis C.
机构信息
a From the Section of Rheumatology, Department of Clinical Sciences Lund , Lund University , Lund , Sweden.
b Department of Rheumatology , Skåne University Hospital , Lund , Sweden.
出版信息
Infect Dis (Lond). 2015;47(12):915-8. doi: 10.3109/23744235.2015.1075659. Epub 2015 Aug 12.
Cartilage oligomeric matrix protein (COMP) is a biomarker of fibrosis in lung and skin. In this exploratory study we investigated the biomarker potential of COMP in chronic hepatitis C (CHC). We included consecutive patients with CHC admitted to the Department of Infectious Diseases, Lund University Hospital. COMP was analysed in serum using ELISA. The correlations between COMP and liver fibrosis, determined by transient elastography (TE) (n = 47) and liver biopsy (n = 28) were assessed. We also studied COMP prospectively in relation to antiviral treatment (n = 10). COMP correlated with the degree of liver fibrosis as assessed by TE (r = 0.71, p < 0.001) and liver biopsy (rs = 0.65, p < 0.001). After successful treatment of CHC, COMP decreased from 18 to 13 U/l (p = 0.011). We suggest that COMP is associated with the stage of liver fibrosis in CHC. The biomarker potential of COMP in CHC warrants further investigation.
软骨寡聚基质蛋白（COMP）是肺和皮肤纤维化的生物标志物。在这项探索性研究中，我们研究了 COMP 在慢性丙型肝炎（CHC）中的生物标志物潜力。我们纳入了连续就诊于隆德大学医院传染病科的 CHC 患者。采用 ELISA 法检测血清中的 COMP。评估了 COMP 与通过瞬时弹性成像（TE）（n = 47）和肝活检（n = 28）确定的肝纤维化之间的相关性。我们还前瞻性地研究了 COMP 与抗病毒治疗（n = 10）的关系。COMP 与 TE（r = 0.71，p < 0.001）和肝活检（rs = 0.65，p < 0.001）评估的肝纤维化程度相关。成功治疗 CHC 后，COMP 从 18 降至 13 U/l（p = 0.011）。我们认为 COMP 与 CHC 中的肝纤维化分期有关。COMP 在 CHC 中的生物标志物潜力值得进一步研究。
Zotero 插件